Corey J. Langer, MD:This is a fairly typical patient that we frequently seea 61-year-old Caucasian female, never-smoker, who presents with shortness of breath and cough, is found on X-ray to have a large right upper lobe mass as well as some other small vague nodules. Her physical exam is fairly unremarkable. There are no palpable nodes. Her lungs are relatively clear. A CAT scan confirmed a fairly large right upper lobe mass with multiple bilateral pulmonary nodules that measured up to 1 to 2 centimeters. As part of her staging, also routinely done, she undergoes an MRI. The MRI shows multiple, albeit asymptomatic, brain metastases. If we look at our newly diagnosed patients with metastatic lung cancer, upward of 15% to 20% will often present with brain metastases.
As part of her work-up, she undergoes a core biopsy of the right upper lobe. This confirms adenocarcinoma. It’s TTF-1positive, which is generally the case in about 75% to 80% of those with adenocarcinoma. Our suspicion for a driver mutation goes up, in light of her nonsmoking history. And, in fact, her tumor does harborEGFRmutations, specifically an exon 19mutation. Further workup shows that her tumor isALK-negative, and, of course, she is negative for theKRASmutation.
She starts treatment in June of 2017 with afatinib and does quite well. Updated scans of her chest show a marked shrinkage of the right upper lobe mass and similar shrinkage or disappearance of many of the pulmonary nodules. Her brain metastases, in the absence of whole brain radiation, Gamma Knife, or stereotactic radiation, also reveal shrinkage on a follow-up brain MRI. As of March of 2018, 9 months after the initiation of treatment, she’s continuing to do quite well.
Transcript edited for clarity.
June 2017
March 2018
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More